Appia Bio is a technology company.
Appia Bio has raised $52.0M across 1 funding round.
Appia Bio has raised $52.0M in total across 1 funding round.
Appia Bio has raised $52.0M in total across 1 funding round.
Appia Bio's investors include 8VC, NanoDimension.
Appia Bio is an early-stage biotechnology company developing off-the-shelf allogeneic cell therapies for cancer patients, primarily targeting hematological and solid tumors.[1][2][4] Founded in 2020 and based in Los Angeles, California, it leverages its proprietary ACUA (Appia Cells Utilized for Allogeneic) platform to engineer CAR-invariant natural killer T (CAR-iNKT) cells from hematopoietic stem cells (HSCs), enabling scalable production of cryopreservable therapies that contrast with patient-specific autologous CAR-T treatments.[1][2][5] The company serves cancer patients and physicians by addressing accessibility barriers in cell therapy, with proceeds from its $52 million Series A financing (raised in 2021, led by 8VC) funding clinical progression.[1][6]
This approach solves key limitations of current therapies, such as high costs, manufacturing variability tied to patient health, and limited scalability, positioning Appia Bio to broaden access to potent innate-like T cells like NKT subtypes.[2][4]
Appia Bio emerged from stealth in May 2021 with its $52 million Series A launch, backed by investors including 8VC, Two Sigma Ventures, Sherpa Healthcare Partners, and Freeflow Ventures.[1] Founded in 2020 in Los Angeles (with operations noted in Culver City), the company was established by a team of pioneering biologists, immuno-engineers, and cell therapy experts, though specific founders are not detailed in available sources.[1][4][5][7]
The idea stemmed from unmet needs in cell therapy: harnessing HSC differentiation to create engineered, universal CAR-iNKT cells, inspired by the Roman Aqua Appia aqueduct's engineering for mass access—mirroring their ACUA platform's goal of scalable, off-the-shelf treatments.[2][4] Early traction included the Series A funding and patent filings in immunology and immune system technologies, setting the stage for clinical advancement in cancer indications.[1][6]
Appia Bio stands out in the cell therapy field through these key advantages:
These elements create a "one powerful, patented platform" for curative potential.[2]
Appia Bio rides the allogeneic cell therapy wave, shifting from bespoke autologous CAR-T (e.g., approved for blood cancers but limited by logistics) to universal, frozen-ready options amid rising demand for solid tumor treatments.[1][2] Timing aligns with 2020s advances in HSC engineering and NK/iNKT cell understanding, fueled by market forces like immunotherapy's growth (e.g., NK cell pipelines including related therapies) and investor interest—evidenced by its quick $52M raise.[1][6]
It influences the ecosystem by pioneering HSC-derived iNKT therapies, potentially lowering barriers for broader adoption, enhancing competition against autologous leaders, and expanding cell therapy to underserved solid tumors.[2][3][5]
Appia Bio is poised to advance its CAR-iNKT programs into clinics for hematological and solid tumors, building on 2021 funding amid a maturing allogeneic field.[1][6] Trends like NK/iNKT pipeline expansion (e.g., therapies like FATE-NK100) and manufacturing innovations will shape its path, with potential for partnerships or further funding to hit milestones.[6] Its influence could grow by proving ACUA's scalability, transforming cell therapy accessibility and tying back to its mission of curative, off-the-shelf cancer medicines for more patients.[4][7]
Appia Bio has raised $52.0M across 1 funding round. Most recently, it raised $52.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $52.0M Series A | 8VC, NanoDimension |